Prognosis is influenced by stage, Integrated Pulmonary Index (IPI) score, molecular subtype, and genetic rearrangements such as MYC, BCL2, or BCL6, with double-hit lymphomas associated with poorer outcomes. This evidence concerns the gene BCL2 and lymphoma.